Effects of simvastatin treatment on oxidant/antioxidant state and ultrastructure of streptozotocin-diabetic rat lung

Cell Biochemistry and Function

Volumn 23, Issue 6, 2005, Pages 421-426

  Ozansoy, Gülgün ^a   Güven, Cengiz ^a   Ceylan, Ash ^a   Can, Belgin ^a   Aktan, Fügen ^a   Öz, Eser ^b   Gönül, Bilge ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Catalase; Glutathione peroxidase; Lung; Malondialdehyde; Simvastatin; STZ diabetes

Indexed keywords

GLUCOSE; GLUTATHIONE PEROXIDASE; LIPID; MALONALDEHYDE; NITRIC OXIDE; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HISTOLOGY; HYPERGLYCEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPID PEROXIDATION; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; ULTRASTRUCTURE;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID PEROXIDATION; LIPIDS; LUNG; MALE; MALONDIALDEHYDE; NITRIC OXIDE; OXIDANTS; OXIDATION-REDUCTION; RATS; RATS, WISTAR; SIMVASTATIN;

ANIMALIA;

EID: 27844478176     PISSN: 02636484     EISSN: None     Source Type: Journal    
DOI: 10.1002/cbf.1168     Document Type: Article

References (35)

1. Cochrane CG. Cellular injury by oxidants. Am J Med 1991; 91(Suppl.): 23S-30S.
2. Kakkar R, Kalra J, Mantha SV, Prassad K. Lipid peroxidation and activity of antioxidant enzymes in diabetic rats. Mol Cell Biochem 1995; 151: 113-119.
3. Freman BA, Capro JD. Biology of disease: free radicals and tissue injury. Lab Invest 1982; 47: 412-426.
4. Wolff SP, Dean RT. Glucose autoxidation and protein modification; the potential role of autoxidative glycosylation in diabetes. Biochem J 1987; 245: 243-250.
5. Morel DW, Hessler JR, Chilsom GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. Lipid Res 1983; 24: 1070-1076.
6. Devlin TM. Textbook of Biochemistry with Clinical Correlation (2nd edn). John Wiley & Sons: New York, 1986; 838-839.
7. Plopper CG, Morishige WK. Alterations in granular (type II) pneumocyte ultrastructure by streptozotocin-induced diabetes in rat. Lab Invest 1978; 38: 143-148.
8. Plopper CG, Morishige WK. Alterations in the ultrastructure of nonciliated bronchiolar epithelial (Clara) cells by streptozotocin -induced diabetes in rats. Am Rev Respir Dis 1979; 120: 1137-1143.
9. Ilingworth DR, Erkeleus DW, Keller U, Thompson G, Tikkanen MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin and simvastatin. Lancet 1994; 343: 1554-1555.
10. Vaugham CJ, Murphy MB, Buddy BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079-1082.
11. Aebi H. Catalase in vitro. Methods in Enzymol 1984; 105: 121-126.
12. Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 1976; 71: 952-958.
13. Yagi K. Lipid peroxides and human disease. Chem Phys Lipids 1987; 45: 337-351.
14. Lowry OH, Rosebrough NJ, Farr JL, Randal RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
15. Taşkiran D, Kutay FZ, Sözmen E, Pöǧün Ş. Sex differences in nitrite/nitrate levels and antioxidant defence in rat brain. Neurorepro 1997; 8: 881-884.
16. West IC. Radicals and oxidative stress in diabetes. Diabet Med 2000; 17: 171-180.
17. Berg TJ, Bangstad HJ, Torjesen PA, Osterby R, Bucala R, Hannsen KF. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 1997; 46: 661-665.
18. Rumble JR, Cooper ME, Soulis T, et al. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest 1997; 99: 1016-1027.
19. Sima A, Popov D, Starodub O, et al. Pathobiology of the heart in experimental diabetes: immunolocalization of lipoproteins, immunoglobulin G and advanced glycation end products proteins in diabetic and/or hyperlipidemic hamster. Lab Invest 1997; 77: 3-18.
20. Ofulue F, Thurlbeck MW. Experimental diabetes and the lung. Am Rev Respir Dis 1998; 138: 284-289.
21. Schleicher ED, Wagner E, Nerlic AG. Increased accumulation of glyoxidation product N(epsilon)- carboxymethyl) lysine in human tissue in diabetes and aging. J Clin Invest 1997; 99: 457-468.
22. Hibbs Jr JB, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988; 157: 87-94.
23. Doroshow JH, Locker GY, Myers CE. Enzymatic defences of the mouse heart against reactive oxygen metabolites. J Clin Invest 1980; 65: 128-135.
24. American Diabetes Association. Management of dyslipidemia in adults with diabetes (position statement). Diabetes Care 1999; 22(Suppl. 1): S56-S59.
25. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-Coenzme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-1131.
26. Reinila A, Koivisto VA, Akerblom HK. Lipids in the pulmonary artery and lungs of severely diabetic rats. A histochemical and chemical study. Diabetologia 1977; 13: 305-310.
27. Fujiwara Y, Kondo K, Itakura H, et al. Regulation of hepatic high density lipoprotein binding protein HB2, expression after administration of simvastatin to rabbit. J Atheroscler Thromb 2000; 7: 203-208.
28. Yasunari K, Maeda K, Minami M, Yoshikawa J. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through supression of increased oxidative stress. Arteroscler Thromb Vac Biol 2001; 21: 937-942.
29. Kim SI, Han DC, Lee HB. Lovastatin inhibits transforming growth factor beta 1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000; 11: 80-87.
30. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001; 108: 1429-1437.
31. Vigano T, Hernandez A, Corsini A, et al. Mevalonate pathway and isoprenoids regulate human bronchiole myocyte proliferation. Eur J Pharmacol 1995; 291: 201-203.
32. Pintaric I, Eterovic D, Tocilj J, Reiner Z, Lusic I. Effect of simvastatin on micropulmonary red cell mass in patients with hyperlipoproteinemia. Atherosclerosis 2001; 154: 493-496.
33. Alfon J, Guasch JF, Berrozpe M, Badimon L. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. Atherosclerosis 1999; 145: 325-331.
34. Reiner Z, Pintaric I, Eterovi D, Tocilj J, Tedeschi-Reiner E. Effects of simvastatin on diffusing capacity in primary hypercholesterolemia. Atherosclerosis 1995; 115: S56.
35. Kozlov AA, Safiullina ZM, Zhuravlera TD, Shalaev SV. Antioxidant activity of lovastatin and simvastatin in survivors of an episode of unstable angina (effect of therapy for 6 months). Kardiologia 2000; 40: 1-15.